Drug Profile


Alternative Names: GMA-102

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gmax Biopharm
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 01 Nov 2017 Phase-II clinical trials in Type-2 diabetes mellitus in Australia and New Zealand (SC) (Gmax Biopharm pipeline of November 2017) (ACTRN12617000811303p)
  • 05 Jun 2017 Gmax Biopharm plans a phase II trial for Type-2 diabetes mellitus in Australia and New Zealand (ACTRN12617000811303p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top